EL7.AI
Stocks•12 June 2026•
1 min read

Anixa Biosciences Buy Ratings Reiterated Following Cancer Vaccine Trial Success

Key Facts

1H.C. Wainwright and Citigroup reiterated 'Buy' ratings for Anixa Biosciences following progress in cancer therapy trials.
2The breast cancer vaccine successfully completed Phase 1 trials, meeting all primary goals and proving safety.
3The ovarian cancer therapy 'lira-cel' showed positive survival observations in its Phase 1 clinical trial.

Amid rapid advancements in the biotechnology sector, Anixa Biosciences is emerging as a promising player following significant clinical milestones. H.C. Wainwright and Citigroup reiterated 'Buy' ratings for the company's stock following tangible progress in cancer therapy trials. The breast cancer vaccine successfully completed Phase 1 clinical trials, proving its safety and meeting all primary goals, while the ovarian cancer therapy 'lira-cel' showed positive survival observations.

These positive results strengthen the company's competitive position against peers in the immunotherapy sector, where firms like Moderna and BioNTech are also racing to develop cancer vaccines. Per market data, the success of Phase 1 is a critical step in de-risking operations for micro-cap biotech firms. Citigroup analysts noted that the preliminary data for 'lira-cel' provides a solid foundation for the upcoming stages of clinical development.

Investors are looking toward further updates from the company's upcoming symposium presentations as potential price catalysts. Additionally, broader market sentiment may be influenced by upcoming global data, such as the China Inflation Rate report on June 10, which impacts overall risk appetite.